Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety surveillance of Vaxem Hib in Korean children
2014-005203-24Phase 4
- Sponsor
- Novartis
- Start
- Dec 2014
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Haemophilus b conjugate vaccine in Haemophilus influenzae type b disease (Hib), sponsored by Novartis. Primary endpoint: Solicited local and systemic reactions within 7 days after each dose.
02
Drugs
Haemophilus b conjugate vaccine
03
Conditions
Haemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2014-005203-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005203-24.